Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 6.9% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) rose 6.9% during trading on Monday . The stock traded as high as $8.66 and last traded at $8.34. Approximately 12,568,478 shares changed hands during trading, a decline of 13% from the average daily volume of 14,385,466 shares. The stock had previously closed at $7.80.

Analyst Upgrades and Downgrades

RXRX has been the subject of several analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp decreased their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $8.75.

Recursion Pharmaceuticals Stock Down 3.1 %

The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm’s 50 day moving average price is $6.91 and its two-hundred day moving average price is $7.02. The firm has a market cap of $2.84 billion, a price-to-earnings ratio of -4.75 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.43) earnings per share. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $6.31, for a total value of $37,860.00. Following the completion of the sale, the chief operating officer now owns 521,138 shares of the company’s stock, valued at $3,288,380.78. The trade was a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Secora sold 15,000 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 55,341 shares of company stock valued at $393,490. Insiders own 15.75% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its stake in shares of Recursion Pharmaceuticals by 20.3% during the second quarter. Bank of New York Mellon Corp now owns 1,060,804 shares of the company’s stock worth $7,956,000 after purchasing an additional 178,994 shares in the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of Recursion Pharmaceuticals by 25.7% during the 2nd quarter. Commonwealth Equity Services LLC now owns 44,241 shares of the company’s stock valued at $332,000 after buying an additional 9,058 shares during the period. Rhumbline Advisers lifted its position in Recursion Pharmaceuticals by 24.1% during the 2nd quarter. Rhumbline Advisers now owns 281,348 shares of the company’s stock worth $2,110,000 after acquiring an additional 54,576 shares in the last quarter. Victory Capital Management Inc. grew its position in Recursion Pharmaceuticals by 13.5% in the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after acquiring an additional 2,598 shares in the last quarter. Finally, Arizona State Retirement System lifted its position in shares of Recursion Pharmaceuticals by 11.1% during the second quarter. Arizona State Retirement System now owns 47,691 shares of the company’s stock worth $358,000 after purchasing an additional 4,760 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.